433 related articles for article (PubMed ID: 8873551)
41. Spinal opioid analgesic effects are enhanced in a model of unilateral inflammation/hyperalgesia: possible involvement of noradrenergic mechanisms.
Hylden JL; Thomas DA; Iadarola MJ; Nahin RL; Dubner R
Eur J Pharmacol; 1991 Mar; 194(2-3):135-43. PubMed ID: 1676373
[TBL] [Abstract][Full Text] [Related]
42. Rotational behavior mediated by dopaminergic and nondopaminergic mechanisms after intranigral microinjection of specific mu, delta and kappa opioid agonists.
Matsumoto RR; Brinsfield KH; Patrick RL; Walker JM
J Pharmacol Exp Ther; 1988 Jul; 246(1):196-203. PubMed ID: 2839661
[TBL] [Abstract][Full Text] [Related]
43. Development of opioid tolerance with repeated transcutaneous electrical nerve stimulation administration.
Chandran P; Sluka KA
Pain; 2003 Mar; 102(1-2):195-201. PubMed ID: 12620611
[TBL] [Abstract][Full Text] [Related]
44. Blocking mu opioid receptors in the spinal cord prevents the analgesic action by subsequent systemic opioids.
Chen SR; Pan HL
Brain Res; 2006 Apr; 1081(1):119-25. PubMed ID: 16499888
[TBL] [Abstract][Full Text] [Related]
45. Stimulation of mu and delta opioid receptors induces hyperalgesia while stimulation of kappa receptors induces antinociception in the hot plate test in the naked mole-rat (Heterocephalus glaber).
Towett PK; Kanui TI; Juma FD
Brain Res Bull; 2006 Dec; 71(1-3):60-8. PubMed ID: 17113929
[TBL] [Abstract][Full Text] [Related]
46. Differential contribution of descending controls to the antinociceptive actions of kappa and mu opioids: an analysis of formalin-evoked C-fos expression.
Gogas KR; Levine JD; Basbaum AI
J Pharmacol Exp Ther; 1996 Feb; 276(2):801-9. PubMed ID: 8632353
[TBL] [Abstract][Full Text] [Related]
47. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
Sheldon RJ; Nunan L; Porreca F
J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
[TBL] [Abstract][Full Text] [Related]
48. Antagonist-induced opioid receptor up-regulation. I. Characterization of supersensitivity to selective mu and kappa agonists.
Millan MJ; Morris BJ; Herz A
J Pharmacol Exp Ther; 1988 Nov; 247(2):721-8. PubMed ID: 2846827
[TBL] [Abstract][Full Text] [Related]
49. The role of nitric oxide in the development of opioid withdrawal induced by naloxone after acute treatment with mu- and kappa-opioid receptor agonists.
Capasso A; Sorrentino L; Pinto A
Eur J Pharmacol; 1998 Oct; 359(2-3):127-31. PubMed ID: 9832382
[TBL] [Abstract][Full Text] [Related]
50. Antinociception by intrathecal midazolam involves endogenous neurotransmitters acting at spinal cord delta opioid receptors.
Goodchild CS; Guo Z; Musgreave A; Gent JP
Br J Anaesth; 1996 Dec; 77(6):758-63. PubMed ID: 9014630
[TBL] [Abstract][Full Text] [Related]
51. The contributions of mu-, delta- and kappa-opioid receptors to the actions of endogenous opioids on spinal reflexes in the rabbit.
Clarke RW; Ford TW
Br J Pharmacol; 1987 Jul; 91(3):579-89. PubMed ID: 3038245
[TBL] [Abstract][Full Text] [Related]
52. Differential effects of intrathecally administered delta and mu opioid receptor agonists on formalin-evoked nociception and on the expression of Fos-like immunoreactivity in the spinal cord of the rat.
Hammond DL; Wang H; Nakashima N; Basbaum AI
J Pharmacol Exp Ther; 1998 Jan; 284(1):378-87. PubMed ID: 9435201
[TBL] [Abstract][Full Text] [Related]
53. Effects of mu, delta and kappa opioid antagonists on the depression of a C-fiber reflex by intrathecal morphine and DAGO in the rat.
Guirimand F; Strimbu-Gozariu M; Willer JC; Le Bars D
J Pharmacol Exp Ther; 1994 Jun; 269(3):1007-20. PubMed ID: 7912273
[TBL] [Abstract][Full Text] [Related]
54. A method to estimate the potency of the mu-component of an opioid having mixed mu-, and kappa- and/or delta-agonist activities.
Liu XF; Fan XT; Kitamura K; Taniguchi T; Oka T
Psychopharmacology (Berl); 1995 Jan; 117(2):166-71. PubMed ID: 7753963
[TBL] [Abstract][Full Text] [Related]
55. Differential cardiovascular and respiratory responses to central administration of selective opioid agonists in conscious rabbits: correlation with receptor distribution.
May CN; Dashwood MR; Whitehead CJ; Mathias CJ
Br J Pharmacol; 1989 Nov; 98(3):903-13. PubMed ID: 2556206
[TBL] [Abstract][Full Text] [Related]
56. Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist--loperamide.
Nozaki-Taguchi N; Yaksh TL
Anesthesiology; 1999 Jan; 90(1):225-34. PubMed ID: 9915332
[TBL] [Abstract][Full Text] [Related]
57. Further study of kappa opioids on increased urination.
Leander JD
J Pharmacol Exp Ther; 1983 Oct; 227(1):35-41. PubMed ID: 6137557
[TBL] [Abstract][Full Text] [Related]
58. The effect of intrathecal mu, delta, kappa, and alpha-2 agonists on thermal hyperalgesia induced by mild burn on hind paw in rats.
Kim HJ; Seol TK; Lee HJ; Yaksh TL; Jun JH
J Anesth; 2011 Dec; 25(6):884-91. PubMed ID: 21983967
[TBL] [Abstract][Full Text] [Related]
59. Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation.
Shook JE; Lemcke PK; Gehrig CA; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1989 Apr; 249(1):83-90. PubMed ID: 2540324
[TBL] [Abstract][Full Text] [Related]
60. Comparison of the spinal actions of the mu-opioid remifentanil with alfentanil and morphine in the rat.
Buerkle H; Yaksh TL
Anesthesiology; 1996 Jan; 84(1):94-102. PubMed ID: 8572360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
